GoodRx Holdings (GDRX) Interest Expenses (2019 - 2026)

GoodRx Holdings has disclosed Interest Expenses across 8 years of filings, most recently posting $9.8 million for Q2 2026.

• In Q2 2026, Interest Expenses fell 8.57% year-over-year to $9.8 million; the TTM figure through Jun 2026 stood at $40.8 million (down 9.49% YoY), while the FY2025 annual figure was $42.6 million, down 19.49% from the prior year.
• Interest Expenses came in at $9.8 million for Q2 2026 at GoodRx Holdings, roughly flat from $9.8 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $14.8 million in Q4 2023 to a low of $5.9 million in Q1 2022.
• Average Interest Expenses over 5 years is $11.4 million, with a median of $11.1 million recorded in 2024.
• Year-over-year, Interest Expenses soared 123.77% in 2023 and dropped 27.31% in 2025.
• Over 5 years, Interest Expenses stood at $11.9 million in 2022, then advanced by 24.26% to $14.8 million in 2023, then declined by 23.37% to $11.4 million in 2024, then fell by 8.41% to $10.4 million in 2025, then fell by 5.7% to $9.8 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $9.8 million in Q2 2026, $9.8 million in Q1 2026, and $10.4 million in Q4 2025.